Get Started

NDTP

PINK NDT Pharmaceuticals, Inc.
Oct 28, 2026 · 2:02 AM ET EOD Market Closed

$0.2000 ↑ +0.0000 (+0.00%) Trading Up from the previous close of $0.2000, $0.0275 below the day’s high of $0.2275

YTD change
-88.83%
vs 20-day SMA
-45.45%
vs 200-day SMA
-76.45%

Price ranges

Previous day
$0.2100 $0.2700
open $0.2700 close $0.2590
-$0.0110 (-4.07%)
Today
$0.1300 $0.2275
open $0.2275 now $0.2000
-$0.0275 (-12.09%)
Past week
$0.2100 $0.5229
from $0.4900 now $0.2000
-$0.2900 (-59.18%)
Past month
$0.2100 $0.5229
from $0.4680 now $0.2000
-$0.2680 (-57.26%)
This year
$0.1300 $1.8000
from $1.7900 now $0.2000
-$1.5900 (-88.83%)

Price & Performance

-0.38 (-65.52%) / 6M

$0.1597$0.3546$0.5494$0.7443Apr 27Jul 14Oct 27

Signals & Sentiment

Momentum, market sentiment, and recent alerts

Poor
  • The stock is 90.5% away from all-time highs of $2.1000
  • NDTP is down 89% since the beginning of the year
  • NDTP is down 83% over the past 12 months
  • NDTP is down 57% over the past 1 month

NDTP reads poor: price sits below both the 20- and 200-day averages, the 12-month move is -83.1%.

Financial Strength

Earnings, valuation, and balance sheet

Earnings

Profitable No
EPS $-0.0036
Earnings momentum N/A Quarterly EPS growth
Quarterly change N/A

Valuation

P/E ratio N/A
Enterprise value $51.8M
Beta 6.55

Balance sheet & scale

IncomeN/A
Revenue$278.5K
Cash$80.9K
Debt$701.0
Income / Debt N/A

Company & Peers

Company profile and competitor comparison

Company profile

ExchangePINK
Market cap $39.4M

NDT Pharmaceuticals, Inc. engages in the business of developing nutraceutical and pharmaceutical products. The company was founded on May 13, 2005 and is headquartered in Liverpool, NY.

Competitor comparison

No peer group available for this symbol.

You looked up one stock
Trade Ideas watches them all

Real-time scanning and AI-generated signals across the entire market.

See plans TI Pro Download

Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.